Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $440

Barclays analyst Luke Sergott has maintained an Overweight rating on West Pharmaceutical Services (NYSE: WST) and raised the price target from $400 to $440. This adjustment reflects a positive outlook for the company in the market.